Orion
Johanna Kela is a Senior Scientist at Orion Corporation, a position held since January 2003, where responsibilities include serving as study director for nonclinical drug development projects focused on chronic pain and exploring novel drug target ideas. Previous roles at Orion Corporation include Team Leader for in vivo laboratory operations related to CNS and a Research Scientist managing a COMT inhibitor project in preclinical settings. Prior to joining Orion Corporation, Johanna Kela undertook a Ph.D. at Karolinska Institutet, conducting research on gene silencing using in vitro and in vivo techniques. Educationally, Johanna Kela earned a Master of Science in Biochemistry from the University of Oulu between 1992 and 1999.
This person is not in the org chart
Orion
1 followers
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.